Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon contact icon menu icon
Medicilon Logo
|
search icon close search icon contact icon menu icon
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Jul 11,2022
Medicilon and BravoBio have reached a strategic collaboration on innovative vaccine IND R&D services
On June 28, 2022, Shanghai Medicilon Inc. (Medicilon) and Shanghai BravoBio Co. Ltd. (BravoBio) signed a strategic collaboration agreement online to officially become the collaboration partner.
More
Medicilon and BravoBio have reached a strategic collaboration on innovative vaccine IND R&D services
Jul 11,2022
To assist preclinical research of RNA drugs, Medicilon and Acon Pharmaceuticals reached a strategic collaboration
On June 24, 2022, Shanghai Medicilon Inc. (Medicilon) and ACON Pharmaceuticals Inc. (ACON) reached a strategic collaboration.
More
To assist preclinical research of RNA drugs, Medicilon and Acon Pharmaceuticals reached a strategic collaboration
Jul 11,2022
Empowering gene therapy, Medicilon and ZY Therapeutics reach a strategic collaboration
On June 28, 2022, Medicilon and ZY Therapeutics signed a strategic collaboration on preclinical IND application services to jointly promote development of gene therapy drugs.
More
Empowering gene therapy, Medicilon and ZY Therapeutics reach a strategic collaboration
Jul 04,2022
Medicilon and Suzhou Langrui have reached a strategic collaboration
On June 19, 2022, Shanghai Medicilon Inc. and Suzhou Langrui Biomedical Co., Ltd. signed a strategic collaboration agreement on innovative drug research and development services.
More
Medicilon and Suzhou Langrui have reached a strategic collaboration
Jul 04,2022
Medicilon assisted Bio-Thera's bispecific neutralizing antibody drug for injection BAT2022 for the treatment of new coronary pneumonia was approved for clinical use
On June 10, 2022, Bio-Thera Solutions, Ltd. (Bio-Thera) announced that BAT2022 for injection has obtained a clinical trial approval.
More
Medicilon assisted Bio-Thera's bispecific neutralizing antibody drug for injection BAT2022 for the treatment of new coronary pneumonia was approved for clinical use
Jul 04,2022
Medicilon reached the strategic collaboration on preclinical IND application services with Welman Pharmaceutical & Mingyu New Drug
On June 23, 2022, Shanghai Medicilon Inc.,Welman Pharmaceutical and Shenzhen Mingyu New Drug Research and Development Co., Ltd. signed a strategic collaboration on preclinical IND application services.
More
Medicilon reached the strategic collaboration on preclinical IND application services with Welman Pharmaceutical & Mingyu New Drug
Jul 04,2022
Medicilon and Xiling Lab formed a strategic partnership
On June 17, 2022, Shanghai Medicilon Inc. and Xiling Lab signed a strategic collaboration agreement on innovative drug research and development services in Tianfu Life Science Park.
More
Medicilon and Xiling Lab formed a strategic partnership
Jul 01,2022
Medicilon and BravoBio held an online ceremony for signing the Strategic Cooperation Agreement
On June 28, 2022, Shanghai Medicilon Inc. ("Medicilon”) and Shanghai BravoBio Co., Ltd ("BravoBio”) held an online ceremony for signing the Strategic Cooperation Agreement, which marks the two companies have officially become cooperative partners.
More
Medicilon and BravoBio held an online ceremony for signing the Strategic Cooperation Agreement
Jun 17,2022
Medicilon Appoints Dr. Jingxuan Zhang as Vice President of Preclinical Toxicology Research
​Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Jingxuan Zhang as the Vice President of the Preclinical Toxicology Research.
More
Medicilon Appoints Dr. Jingxuan Zhang as Vice President of Preclinical Toxicology Research
Jun 10,2022
Medicilon Assists | China's First CD19×CD3×CD28 Trispecific Antibody Obtained FDA Implicit Approval
Shanghai Medicilon Inc. (Medicilon) provided CC312 with a comprehensive preclinical study (including pharmacokinetics and safety evaluation) that complied with GLP specifications with compliant, efficient and high-quality services.
More
Medicilon Assists | China's First CD19×CD3×CD28 Trispecific Antibody Obtained FDA Implicit Approval
May 18,2022
Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department
Recently, Shanghai Medicilon Inc. (Medicilon, stock code: 688202.SH) announced the appointment of Dr. Jing Deng as the Vice President of the Pharmacology and Biology Department.
More
Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department
May 06,2022
Medicilon Assist| Sinovent's New Class 1 Anti-tumor Drug XNW14010 has been Approved for Clinical Trials
​Recently, the State Drug Administration approved the clinical application of XNW14010, a new class 1 anti-tumor drug from Evopoint Biosciences Co., Ltd. (hereinafter referred to as "Sinovent"), which is intended for the treatment of patients with Advanced solid tumors with KRAS G12C mutation.
More
Medicilon Assist| Sinovent's New Class 1 Anti-tumor Drug XNW14010 has been Approved for Clinical Trials